Myriad Genetics (NASDAQ:MYGN) Issues Q4 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN) issued an update on its fourth quarter earnings guidance on Wednesday morning. The company provided earnings per share guidance of $0.03-0.04 for the period, compared to the consensus earnings per share estimate of $0.03. The company issued revenue guidance of $209-211 million, compared to the consensus revenue estimate of $212.87 million. Myriad Genetics also updated its FY 2025 guidance to 0.070-0.110 EPS.

Myriad Genetics Trading Down 4.2 %

Shares of MYGN opened at $13.68 on Wednesday. The stock has a market cap of $1.25 billion, a PE ratio of -10.52 and a beta of 1.89. The stock has a 50 day simple moving average of $15.05 and a 200-day simple moving average of $22.17. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05. Myriad Genetics has a 1 year low of $12.87 and a 1 year high of $29.30.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on MYGN. Morgan Stanley dropped their price target on Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating for the company in a report on Monday, November 18th. Leerink Partnrs downgraded shares of Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 9th. Leerink Partners lowered Myriad Genetics from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $30.00 to $21.00 in a research report on Monday, December 9th. Piper Sandler dropped their target price on shares of Myriad Genetics from $30.00 to $24.00 and set a “neutral” rating for the company in a research report on Monday, November 11th. Finally, StockNews.com raised Myriad Genetics from a “hold” rating to a “buy” rating in a research note on Thursday, January 9th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Myriad Genetics currently has a consensus rating of “Hold” and a consensus price target of $24.27.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.